Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 10/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18178259 | 0.94 | MRGPRX4 (0.40) | FABP4FABP5MRGPRX4CD274PDCD1 | |
| SCHEMBL18178359 | 0.92 | MRGPRX4 (0.40) | FABP4FABP5MRGPRX4CD274PTGDR2 | |
| SCHEMBL18178139 | 0.91 | MRGPRX4 (0.38) | FABP4FABP5MRGPRX4CD274PDCD1 | |
| SCHEMBL18178362 | 0.90 | FABP4 (0.38) | FABP4FABP5MRGPRX4CD274PTGDR2 | |
| SCHEMBL18178380 | 0.90 | MAPT (0.42) | MRGPRX4CD274PTGDR2ANO1 | |
| SCHEMBL18178726 | 0.89 | MRGPRX4 (0.38) | FABP4FABP5MRGPRX4CD274PTGDR2 | |
| SCHEMBL18178353 | 0.88 | MRGPRX4 (0.40) | FABP4FABP5MRGPRX4CUL4APTGER1 | |
| SCHEMBL18178356 | 0.88 | SLC22A12 (0.41) | FABP4FABP5MRGPRX4CUL4A | |
| SCHEMBL18178280 | 0.88 | LMNA (0.38) | FABP4FABP5MRGPRX4PTGDR2ANO1 | |
| SCHEMBL18178048 | 0.88 | MRGPRX4 (0.48) | MRGPRX4CD274PTGER1PTGER4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573904-B2 | Aromatic compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20160311775-A1 | AROMATIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311775-A1 | AROMATIC COMPOUND AND USE THEREOF | ZCCHC8, CBR3, CBX8 | FABP4 4134/4885FABP5 3786/4885MRGPRX4 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.